To study the role of pre-treatment microRNA (micro ribonucleic acid) expression as a predictor of response to chemoradiation in locally advanced carcinoma cervix.
Adult
Aged
Biomarkers, Tumor
/ analysis
Biopsy
Carcinoma
/ genetics
Cervix Uteri
/ pathology
Chemoradiotherapy
/ statistics & numerical data
Disease-Free Survival
Female
Gene Expression Regulation, Neoplastic
Humans
MicroRNAs
/ analysis
Middle Aged
Response Evaluation Criteria in Solid Tumors
Up-Regulation
Uterine Cervical Neoplasms
/ genetics
biological markers
carcinoma cervix
concurrent chemoradiotherapy
microRNAs
prognosis
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
14
12
2020
received:
12
08
2020
accepted:
19
01
2021
pubmed:
5
3
2021
medline:
5
2
2022
entrez:
4
3
2021
Statut:
ppublish
Résumé
Concurrent chemoradiotherapy followed by brachytherapy is the standard of care in locally advanced carcinoma cervix. There is no prognostic factor at present to predict the outcome of disease in locally advanced carcinoma cervix. Differential expression of microRNAs can be used as biomarkers to predict clinical response in locally advanced carcinoma cervix patients. Thirty-two patients of locally advanced carcinoma cervix with International Federation of Gynecology and Obstetrics Stage IB-IVA were enrolled from 2017 to 2018. Expression of microRNA-9 5p, -31 3p, -100 5p, -125a 5p, -125b-5p, and -200a 5p in formalin-fixed paraffin embedded (FFPE) biopsied tissue were analyzed by real time quantitative reverse transcriptase polymerase chain reaction (RT qPCR). Pretreatment evaluation was done with clinical examination and MRI pelvis. All patients received concurrent chemoradiotherapy followed by brachytherapy. Patients were evaluated for the clinical response after 3 months of treatment, with clinical examination and MRI pelvis scan using RECIST 1.1 criteria. Patients with no residual disease were classified as Complete responders (CR) and with residual or progressive disease were classified as Nonresponders (NR). Results were statistically analyzed using Mann Whiney U test to examine significant difference between the expression of microRNA between complete responders (CR) and nonresponders (NR). microRNA-100 5p was upregulated in complete responders (CR) which showed a trend towards statistical significance (p value = 0.05). microRNA-100 5p can serve as a potential molecular biomarker in predicting clinical response to chemoradiation in locally advanced Carcinoma cervix. Its role should be further investigated in a larger study population.
Sections du résumé
BACKGROUND
Concurrent chemoradiotherapy followed by brachytherapy is the standard of care in locally advanced carcinoma cervix. There is no prognostic factor at present to predict the outcome of disease in locally advanced carcinoma cervix.
AIM
Differential expression of microRNAs can be used as biomarkers to predict clinical response in locally advanced carcinoma cervix patients.
METHODS
Thirty-two patients of locally advanced carcinoma cervix with International Federation of Gynecology and Obstetrics Stage IB-IVA were enrolled from 2017 to 2018. Expression of microRNA-9 5p, -31 3p, -100 5p, -125a 5p, -125b-5p, and -200a 5p in formalin-fixed paraffin embedded (FFPE) biopsied tissue were analyzed by real time quantitative reverse transcriptase polymerase chain reaction (RT qPCR). Pretreatment evaluation was done with clinical examination and MRI pelvis. All patients received concurrent chemoradiotherapy followed by brachytherapy. Patients were evaluated for the clinical response after 3 months of treatment, with clinical examination and MRI pelvis scan using RECIST 1.1 criteria. Patients with no residual disease were classified as Complete responders (CR) and with residual or progressive disease were classified as Nonresponders (NR). Results were statistically analyzed using Mann Whiney U test to examine significant difference between the expression of microRNA between complete responders (CR) and nonresponders (NR).
RESULTS
microRNA-100 5p was upregulated in complete responders (CR) which showed a trend towards statistical significance (p value = 0.05).
CONCLUSION
microRNA-100 5p can serve as a potential molecular biomarker in predicting clinical response to chemoradiation in locally advanced Carcinoma cervix. Its role should be further investigated in a larger study population.
Identifiants
pubmed: 33660436
doi: 10.1002/cnr2.1348
pmc: PMC8388174
doi:
Substances chimiques
Biomarkers, Tumor
0
MIRN100 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1348Informations de copyright
© 2021 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Cancer Lett. 2012 Apr 28;317(2):184-91
pubmed: 22120675
Cancer Rep (Hoboken). 2021 Aug;4(4):e1348
pubmed: 33660436
Curr Opin Oncol. 2005 Sep;17(5):485-92
pubmed: 16093801
Gynecol Oncol. 2016 Sep;142(3):557-65
pubmed: 27423381
N Engl J Med. 2005 Oct 27;353(17):1793-801
pubmed: 16251535
PLoS One. 2008 Jul 02;3(7):e2557
pubmed: 18596939
Cancer Res. 2007 Aug 15;67(16):7713-22
pubmed: 17699775
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
J Cell Biochem. 2020 Feb;121(2):1716-1727
pubmed: 31595566
Cell Res. 2008 Oct;18(10):997-1006
pubmed: 18766170
Eur J Cancer. 2014 May;50(8):1541-54
pubmed: 24559685
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Nat Rev Cancer. 2006 Nov;6(11):857-66
pubmed: 17060945
Nature. 2005 Feb 17;433(7027):769-73
pubmed: 15685193
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Br J Cancer. 2013 May 14;108(9):1817-21
pubmed: 23591197
Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4262-7
pubmed: 24591631
Cell Cycle. 2005 Sep;4(9):1179-84
pubmed: 16096373
Curr Opin Genet Dev. 2005 Oct;15(5):563-8
pubmed: 16099643
PLoS One. 2010 Oct 29;5(10):e13735
pubmed: 21060830
Eur J Cancer. 2011 Sep;47(14):2166-74
pubmed: 21636267
Oncogene. 2006 Oct 9;25(46):6188-96
pubmed: 17028598
BMC Cancer. 2018 Jan 12;18(1):74
pubmed: 29329575
Cancer Res. 2010 Feb 15;70(4):1441-8
pubmed: 20124485
Am J Cancer Res. 2015 Jan 15;5(2):545-59
pubmed: 25973296
J Biol Chem. 2013 Mar 22;288(12):8750-8761
pubmed: 23364795
Radiother Oncol. 2014 Feb;110(2):355-61
pubmed: 24502970
Exp Mol Med. 2011 May 31;43(5):298-304
pubmed: 21464588
Cell. 2005 Jan 14;120(1):15-20
pubmed: 15652477
J Pathol. 2011 Aug;224(4):484-95
pubmed: 21503900
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Asian Pac J Cancer Prev. 2014;15(2):917-23
pubmed: 24568519